20-[[1-Carboxy-4-oxo-4-[2-[2-[2-oxo-2-[2-[2-(2-oxopropoxy)ethoxy]ethylamino]ethoxy]ethoxy]ethylamino]butyl]amino]-20-oxoicosanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 20-[[1-Carboxy-4-oxo-4-[2-[2-[2-oxo-2-[2-[2-(2-oxopropoxy)ethoxy]ethylamino]ethoxy]ethoxy]ethylamino]butyl]amino]-20-oxoicosanoic acid
• 英文别名: 20-[[1-carboxy-4-oxo-4-[2-[2-[2-oxo-2-[2-[2-(2-oxopropoxy)ethoxy]ethylamino]ethoxy]ethoxy]ethylamino]butyl]amino]-20-oxoicosanoic acid
• 化学式: C₃₈H₆₉N₃O₁₂
• 分子量: 760.0
• InChiKey: HWKWHDALIBAUAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  53
• 可旋转键数：
  40
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  216
• 氢给体数：
  5
• 氢受体数：
  12

文献信息

• [EN] TRIPLE AGONIST FOR GLP-1, GCG AND GIP RECEPTORS<br/>[FR] AGONISTE TRIPLE POUR RÉCEPTEURS GLP-1, GCG ET GIP<br/>[ZH] GLP-1、GCG和GIP受体的三重激动剂
  申请人：[en]SUNSHINE LAKE PHARMA CO., LTD.;[zh]广东东阳光药业有限公司

  公开号：WO2022268029A1

  公开（公告）日：2022-12-29

  提供一种GLP-1、GCG和GIP受体的三重激动剂，提供的化合物对胰高血糖素样肽-1(GLP-1)受体、胰高血糖素(GCG)受体和葡萄糖依赖的肠促胰岛素(GIP)受体都具有强的激动活性；其可用于治疗和/或预防包括糖尿病、肥胖症、脂肪肝病、非酒精性脂肪性肝疾病、非酒精性脂肪性肝炎、血脂异常和代谢综合征及相关病症在内的代谢紊乱。
• Novel N-Terminally Modified Insulin Derivatives
  申请人：Madsen Peter

  公开号：US20140315797A1

  公开（公告）日：2014-10-23

  The invention is related to novel N-terminally modified insulin derivatives, pharmaceutical compositions comprising such and methods of making such.
• BIFUNCTIONAL COMPOUNDS COMPRISING INSULIN PEPTIDES AND EGF(A) PEPTIDES
  申请人：Novo Nordisk A/S

  公开号：US20220009989A1

  公开（公告）日：2022-01-13

  The present invention relates to novel covalently linked bi-functional fusion proteins comprising insulin and EGF(A) analogues or derivatives thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such bi-functional compounds, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes and dyslipidaemia associated with diabetes.
• POLYPEPTIDES AND USES THEREOF
  申请人：MEDIMMUNE LIMITED

  公开号：US20220204580A1

  公开（公告）日：2022-06-30

  Disclosed are polypeptides which are pramlintide analogues and uses thereof. In particular, the present invention relates to polypeptides of SEQ ID NO 2 which are pramlintide analogues conjugated to half-life extending moieties such as albumin binding moieties and uses thereof.